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Immunotoxin on Human Glioma Cells in Vitro1
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Departments of Neurology [L. D. R.Â¡and Medicine (Oncology) [T. H'. G., A. R. S.J, University of Massachusetts Medical Center, Worcester, Massachusetts 01605, and
Boston Biomedicai Research Institute, Boston, Massachusetts 021H Â¡V.R.]
ABSTRACT
The cytotoxic effects of an antihuman transferrin receptor monoclonal
antibody-ricin A-chain conjugate (anti-TfR-A) immunotoxin on glioma
cells were assessed in vitro. Five human glioma cell lines were studied;
three were derived from surgical expiants (MG-1, MG-2, MG-3) and
two were well characterized established glioma cells (U-87 MG, U-373
MG). The C6 rat glioma line served as a nonhuman control. One of six
lines (U-373) expressed glial fibrillar) acidic protein, as assessed by
immunohistochemistry. All five human lines expressed human transferrin
receptor, as assessed by flow cytometry; no human transferrin receptor
was demonstrable on rat C6 cells. Potent inhibition of protein synthesis
was found after an 18-h incubation with anti-TfR-A. Fifty % inhibitory
concentration (!(Â«â€ž)values for human glioma cells ranged from 1.9 x
Ml" to 1.8 x 10 " M. In contrast, no significant inhibition of leucine
incorporation was observed when anti-TfR-A was tested on rat cells (ICÂ»
> HI M) or when a control immunotoxin directed against carcinoem-
bryonic antigen was substituted for anti-TfR-A on human glioma cells(U MI> 10~7M). Coincubation with the carboxylic ionophore monensin
(Id ' M) decreased the IGÂ»of anti-TfR-A against human glioma lines
from 16- to 842-fold (range, 7.0 x 10~1!to 1.5 x 10~'Â°M). In contrast,
an IGÂ«of >10"7M was obtained when C6 cells were incubated with anti-
TfR-A and monensin. Anti-TfR-A immunotoxins potentiated by monen
sin are extremely potent in vitro cytotoxins for human glioma cells.
INTRODUCTION
The prognosis for patients with GBM,3 the most common
primary brain neoplasm, remains poor despite intensive com
bined modality conventional treatments, including surgery, ra
diation, and chemotherapy (1); therefore, new strategies that
could either supersede or complement current therapies are
needed. Immunotherapy represents one alternative approach.
Previously, immunotherapeutic treatment of brain tumors
aimed to increase host antitumor defense mechanisms; patient
immunization with glioma cells (2), administration of inter-
feron (3), or, more recently, intratumoral delivery of interleukin
2 and lymphokine-activated killer cells (4) all represent exam
ples of such a strategy. An alternative immunotherapy would
utilize MoAbs directed against tumor-associated antigens to
selectively deliver toxins into tumor cells. The administration
of such ITs may result in potent and specific tumor cell killing.
In order to achieve selective effects using immunotoxins,
antigens which are exclusively or differentially expressed on
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tumor cells should be chosen as targets, so that adverse effects
will be minimal. The optimal target, therefore, would be an
antigen that is exclusively expressed on tumor cells; unfortu
nately, although a number of tumor membrane components,
such as epidermal growth factor receptor (5, 6), appear to be
present in higher numbers of glioma cells, a completely specific
glioma membrane component has not yet been demonstrated.
Nevertheless, antigens that are expressed in much higher con
centrations on glioma cells, compared to normal neural tissues,
might still make acceptable immunotherapeutic targets. One
such candidate membrane component is the TfR, a cell surface
glycoprotein whose expression on the cell surface is coordi-
nately regulated with cell growth.
A number of observations suggest that TfR is differentially
expressed in gliomas, compared to normal surrounding neural
tissues. TfR immunostaining can be detected in virtually all
primary brain tumors in amounts much higher than in normal
surrounding tissues; furthermore, staining intensity tends to
correlate with tumor anaplasia (7). In addition, TfR expression
can often be demonstrated on human glioma lines in vitro (8-
10). These observations suggest that high TfR expression is a
frequent occurrence in gliomas and that this receptor might be
a suitable target for IT therapy.
Previous studies using ITs constructed with anti-TfR murine
MoAbs as carrier molecules have demonstrated potent effects
on human glioma cells in vitro when attached to either whole
ricin or modified diphtheria toxins (11, 12). However, both of
these toxins present difficulties for clinical use. Whole ricin
conjugates may be limited due to potential toxicity caused by
nonspecific B-chain binding. ITs derived from diphtheria toxin
could be hampered by neutralizing antibodies, due to the almost
universal prior immunization of the adult population. These
difficulties are avoided by using ricin A-chain-based immuno
toxins, which may be more suitable for clinical use. Therefore,
this study was conducted to investigate (a) the level of TfR
expression on a number of glioma cell lines, (b) the cytotoxic
effects of a ricin A-based IT directed against the TfR found on
glioma cells, and (c) the enhancement of cytotoxicity by the
known potentiator monensin.
MATERIALS AND METHODS
Chemicals. Monensin was purchased from Sigma Chemical Co. (St.Louis, MO). The ionophore was prepared as a 10~3M stock solution in
ethanol and diluted to an appropriate final concentration of 0.14 M
NaCl, 0.01 M NaHPO4, pH 7.4 (phosphate-buffered saline).
MoAbs and ITs. The 7D3 MoAb (IgGl), directed against the human
TfR, was produced in mice by injection of cultured human leukemia
CEM cells (13). The anti-carcinoembryonic antigen murine MoAb
(IgG 1) was a gift of Abbott Laboratories. Native ricin A-chain (Inland
Laboratories and EY Laboratories) was disulfide-linked to anti-TfR
and anti-carcinoembryonic antigen with the /V-succinimidyl-3-(2-pyri-
dyldithio)proprionate reagent, to produce immunotoxins (13).
Cell Lines. MG-1, MG-2, and MG-3 were established from primary
expiants of tumors removed from three male patients, 49, 58, and 61
years old, respectively. The pathological diagnosis of each tumor was
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GBM. The primary tumors contained large numbers of TfR-positive
cells, as assessed immunohistochemically (7). U-87 and U-373 were
purchased from the American Type Culture Collection (Rockville,
MD). C6 rat glioma cells were a gift of Dr. William Shapiro (Memorial
Sloan Kettering Cancer Center, New York, NY). All cell lines were
maintained by serial passage in monolayer culture, using RPMI 1640-
10% PCS at 37Â°Cin a humidified atmosphere of 5% CO2.
Immunofluorescent Staining for Human TfR. Growing cultures were
trypsinized and a trypan blue exclusion test was performed to ensure
that >99% of the cells remained viable. Tumor cells (IO6) were incu
bated for l h with 10 Mg of either anti-TfR or MOPC21 (Sigma
Immunochemicals, St. Louis, MO), a nonspecific murine monoclonal
immunoglobulin which served as a control. The cells were washed twice
in MEM and resuspended in I ml phosphate-buffered saline containing
l Â¿igfluorescein isothiocyanate-labeled goat anti-mouse antibody (Bec-
ton-Dickinson, San Jose, CA). After two further washes, the cells were
fixed in 1% paraformaldehyde. Flow cytometric analysis was performed
on a FACSCAN (BDIS, Mountain View, CA). The fluorescence inten
sity of 10,000 viable cells was measured.
GFAP Immunochemistry. In order to better characterize the tumor
cell lines, immunostaining for the specific glial intermediate filament
GFAP was performed. Tumor cells were grown on coverslips, fixed in
acetone for 10 min, and incubated in 3% H2O2 with 1% bovine serum
albumin for an additional 10 min. Slides were then incubated overnight
in a solution containing murine anti-GFAP MoAb (Dakopatts Co.,
Glostrop, Denmark) diluted 1:2000 in 1% normal porcine serum in
Tris buffer, at 4"C. After two washings in Tris-HCl buffer, slides were
then incubated l h in a solution containing a 1:50 dilution of rabbit
anti-mouse antibody (Dakopatts Co.), washed in Tris-HCl, and then
reacted for l h with a 1:200 dilution of peroxidase antiperoxidase.
After a final wash, the peroxidase reaction was developed with diami-
nobenzidine for 10 min, rinsed with water, and then counterstained
with Harris hematoxylin.
Cytotoxicity Assays. For cytotoxicity assays, cells in 75-cnr flasks
were treated with 1 ml 0.05% trypsin, 0.02% EDTA, for 2 min, after
which the trypsin-EDTA solution was removed, leaving only a thin
coating on the cells for an additional 8 min. Leucine-free MEM (10
ml) was added and cells were aspirated and expelled using a syringe
and 22-gauge needle, after which they were seeded into microtiter plates
(IO5 cells/well) (Becton-Dickinson Labware, Oxnard, CA) containing
leucine-free MEM, to a final volume of 200 ^I/well. Additions of serial
dilutions of either anti-TfR-A or control immunotoxin (10~7 to 10~13
M) were made in quadruplicate. Following an 18-h incubation at 37Â°C
in 5% CO2, the medium was removed and replaced with leucine-free
MEM supplemented with 2 ^Ci/well [3H]leucine (New England Nuclear
Corp., Boston, MA). Following an additional 2-h incubation, the me
dium was removed, the cells were treated with 0.05% trypsin, 0.02%
EDTA (200 ^I/well), for 30 min and collected onto glass fiber filters,
and incorporation of [3H]leucine was measured by liquid scintillation
counting of glass fiber discs.
To assess MON potentiation, similar experiments were carried outin the presence of IO"7 M levels of the ionophore.
The inhibitory effect of BCNU on cell growth was also evaluated, to
compare the effects of ITs and chemotherapy on glioma cells. Glioma
cells (5 x IO3)were seeded into 24-well plates containing RPMI 1640
supplemented with 10% FCS. Additions of serial dilutions of BCNU(10~4to 10~8M) were made in triplicate. After an 18-h incubation, the
medium was decanted and replaced with RPMI 1640-10% FCS. Cells
were trypsinized and counted 5 days later.
RESULTS
Flow cytofluorometric analysis revealed that greater than
95% of cells from all five human glioma cell lines bound the
anti-TfR MoAb (7D3), indicating the presence of cell surface
human TfR (Table 1, Fig. la). In contrast, there was no
difference between the binding of the specific anti-human TfR
and control MOPC21 binding to the C6 rat glioma cell line
Table I GFAP and human TfR expression on glioma cell lines
The presence of GFAP was assessed in vitro by immunohistochemical means,
as described in "Materials and Methods." â€”.no visuali/ed cell immunostaining;
+. greater than 90% of cells were immunostained. Mean fluorescence intensity
compares fluorescence intensity on glioma cells after incubation with either anti-
human TfR murine MoAb 7D3 or control murine MoAb MOPC-21.
Log mean fluorescence in
tensity with
CelllineU-373U-87MG
1MG
2MG-3C6GFAP
Anti-TfR+
250300190100905MOPC-212510432155
U-373
10' 102 10s
Fluorescence Intensity
C6
10 10' 10> 10J
Fluorescence Intensity
â€¢
Fig. 1. Characterization of glioma lines. Results of flow cytomelric analysis
of human TfR cell surface expression in U-373 (a) and C6 rat glioma (h) lines.. control MOPC-21 MoAb; . 7D3 anti-TfR MoAb. c, GFAP immu o
staining of U-373 cells. Greater than 95% of cells are positively immuno
stained. x 300.
(Fig. lÃ²).GFAP cell immunostaining was present in only one
(U-373 MG) of the six malignant cell glioma lines (Table 1,
Fig. \c).
Cytotoxic Effects of Anti-TfR-A IT on Glioma Cell Lines. The
anti-TfR-A IT was a potent inhibitor of protein synthesis in all
five human glioma cell lines tested, while the unmodified 7D3
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anti-human TfR MoAb produced no effect (Table 2). The mean
IC50 values obtained ranged from 1.9 x 10~9 to 1.8 x IO"8 M
and were comparable for both the early passage cells and the
established cell lines. This cytotoxicity was specific for the TfR,
since the anti-CEA-A control IT was ineffective against human
glioma cells (IC50 > 10~7 M) (Fig. 2). Similarly, the human
specific anti-TfR-A IT displayed negligible effects on rat C6
glioma cells (IC50 > IO"7 M) (Fig. 3).
Potentiation of IT Effects by MON. MON alone did not
inhibit glioma cell protein synthesis at concentrations as high
as IO'7 M. Coincubation of IO'7 M MON with anti-TfR-A,
however, potentiated IT effects on all five glioma lines from
16- to 842-fold (Table 2) and reduced the mean IC50 levels to
1.5 x 10"" to 7.0 x 10~12 M. By contrast, MON did not
potentiate the effects of either the anti-TfR-A IT on rat C6
glioma cells (Fig. 3) or the anti-TfR-A IT on human glioma
(Fig. 2).
The combined effects of anti-TfR-A IT plus monensin pro
duced very effective cytotoxicity for human GBM cells. By
comparison, BCNU, the standard clinical chemotherapeutic
agent for GBM, was 100,000-fold less potent when tested on
MG-3 cells under similar conditions (IC50 of BCNU was 4.0 x
Table 2 Effect ofanti-TfR MoAb and anti-TfR-A IT on in vitro glioma cell Â¡'HJ
leucine incorporation
Additions of serial dilutions of either 7D3 or anti-TfR-A IT (in the presence
or absence of IO'7 M MON) were incubated with 100.000 glioma cells for 18 h.
after which the medium was removed and replaced with leucine-free MEM,
supplemented with 2 Â»iCi/well[3H|leucine, for 2 h. Incorporation of tritiated
leucine was measured by liquid scintillation counting of glass fiber disks. Results
represent mean K â€žvalues; figures in parentheses denote the number of times
individual experiments were performed.
Mean IC,â€ž(M)Â°Cell
lineU-373
U-87
MG-1
MG-2
MG-3
C6Anti-TfR>10-7(2)
>IO-'(2)
NDC
ND
ND
NDAnti-TfR-A1.9X
10-' (4)
5.9 x 10-' (4)
1.8X 10-' (3)
2.4 x IO'' (3)
1.8 X 10-'(1)
>10-'(3)Anti-TfR-A
+
MON(IO"7M)1.5
x 10-"(4)
7.0 x IO"12(4)
7.0 x IO"" (3)
1.5 x 10-'Â°(3)
4.1 x 10"" (1)
>10-7(3)Potentiating
effect*126
842
257
16
44
* IC50, concentration which resulted in 50% inhibition of protein synthesis.
* Potentiating effect, potentiating effect of added MON (IC!0 anti-TfR-A/IC50
anti-TfR-A plus MON).
' ND. experiment not performed.
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Fig. 3. Inhibition of |3H]leucine incorporation by U-87 and C6 rat glioma
cells after an 18-h incubation with anti-TfR-A. A, C6 glioma cells; A, C6 rat
glioma cells plus IO"7 M MON; O, U-87 human glioma cells; â€¢,U-87 glioma
cells in the presence of IO"7 M MON.
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Fig. 4. Comparison of the effects of the chemotherapeutic agent BCNU (A)
and of anti-TfR-A with (â€¢)and without (O) 10~7M MON on MG-3 cells.
10"' Mversus 4.0 x 10-" M for anti-TfR-A IT plus MON) (Fig.
4).
10 10
IT CONCENTRATION (M)
Fig. 2. Inhibition of [3H|leucine incorporation by MG-1 glioma cells after 18-
h incubations with anti-TfR-A or an anti-CEA-A IT, with or without IO"7 M
MON. A, anti-CEA-A IT; A. anli-CEA-A IT in the presence of IO"7 M MON; O,
anti-TfR-A IT; â€¢.anti-TfR-A IT in the presence of 10~7M MON.
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DISCUSSION
The TfR is a major immunodominant cell surface glycopro-
tein whose expression on the cell surface is coordinately regu
lated with cell growth (14-16). Proliferating cells express
greater numbers of TfR compared to normal tissues, and very
high TfR levels have been noted in certain tumors (16-18).
Administration of MoAbs directed against TfR can inhibit cell
growth, albeit modestly, in some tumor systems (19, 20). By
conjugating anti-TfR MoAbs with an intracellular toxin, more
potent antitumor effects have been obtained against a number
of systemic human cancer lines both in vitro (21, 22) and in
v/vo(13, 23).
Recent evidence has indicated that malignant brain tumor
cells express high numbers of TfR. Therefore, TfR expression
has been noted on malignant glioma cell lines in vitro, utilizing
immunohistochemistry, slot blot RNA analysis, and flow cy-
tometry (8-10). Furthermore, immunohistochemical studies
indicate high levels of TfR in tumor, as compared to normal
brain tissue (7), and the amount of TfR detected by radio-
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immunoassay is much greater in tumor than in surrounding
brain (11). Such differential expression on malignant glial com
pared to normal cells suggests that this membrane component
may be a suitable target for brain tumor immunotherapy.
Zovickian et al. (12) have demonstrated potent effects of
TfR-targeted ITs on human GBM cells in vitro, utilizing an
anti-TfR MoAb conjugated to whole ricin toxins; this effect
was enhanced by coincubation of IT with MON. Subsequent
studies from this group utilizing point-mutated diphtheria toxin
confirmed the effectiveness of anti-TfR MoAbs as carrier mol
ecules of intracellular toxins to brain tumor cells (11). A related
approach to target brain tumor TfR has employed the use of
human transferrin-ricin A-chain conjugates. Effective killing of
a human glioma line was observed in vitro and the specific
cytotoxicity of this conjugate was enhanced more than 100-fold
in the presence of MON.
In the present study, human TfR expression was demon
strated on the five human glioma lines examined, by using flow
cytometric techniques. The fact that targeting the TfR allowed
adequate toxin internalization is supported by the cytotoxicity
studies showing potent effects of anti-TfR-A IT on protein
synthesis. By contrast, an anti-CEA-A [an antigen which is not
expressed in human brain tumors (24)] IT resulted in no cyto
toxicity, nor was anti-TfR-A effective against rat C6 glioma
cells, which do not express human TfR as assessed by flow
cytometry. Furthermore, the effects of anti-TfR-A were not
well correlated with GFAP expression, cell passage number, or
cell doubling times.
One method of potentiating ricin A-chain action in vitro
makes use of the carboxylic ionophore MON, which accelerates
ricin A-chain action by as yet unclear mechanisms (25). MON
was a very effective potentiator of IT action in this study;
therefore, the toxic potency of anti-TfR-A on glioma cells was
increased on average 100-fold by coincubation with this iono
phore. Compared with BCNU, the standard chemotherapy
agent utilized in malignant brain tumor treatment, anti-TfR-A
ITs plus monensin were 100,000 times more potent. Further
more, the selective advantage of this IT on surface human
glioma compared to control TfR-negative C6 cells is over
10,000-fold.
Although anti-TfR-A is an effective inhibitor of glioma cell
protein synthesis in vitro, its therapeutic effectiveness in vivo
may be restricted by the presence of TfR in normal brain. TfR
has a wide CNS distribution in a pattern distinct from that of
iron distribution (26-28). Although its CNS development and
differentiation, especially myelination (28-30). TfR expression
is especially prominent on cerebral oligodendrocytes and endo-
thelial cells (31-33). The presence of CNS TfR raises the
possibility of significant brain toxicity if an anti-TfR IT is
utilized to treat malignant glioma. Nevertheless, even though
antigen expression on normal cells is undesirable, anti-TfR ITs
may still be therapeutically effective if the cell surface antigen
concentration on normal cells is below that required for IT
efficacy (34, 35). The observation that Tf-linked toxins have
been administered intrathecally without undue toxicity to ex
perimental animals (11) suggests, in fact, that toxicity may be
minimal and that carrier molecules directed at TfR may be
useful therapeutically, at least in meningea! malignancies.
Unfortunately, an intrathecal approach is unlikely to be effi
cacious in GBM because intratumoral penetration will be poor.
A preferable route of administration might be via an intrale-
sional or intratumoral route, such as has been clinically utilized
recently with lymphokine-activated killer cells with or without
concomitant interleukin 2 (4, 36). This method of delivery
would have the dual advantages of maximizing tumor penetra
tion while minimizing normal tissue exposure. In vivo studies
are in progress to examine this possibility.
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